Pharmacological treatment of obesity: an overview of different groups of anti-obesity drugs available in Poland
DOI:
https://doi.org/10.12775/JEHS.2024.58.004Keywords
Anti-obesity agents, GLP-1 receptor agonists, weight loss, overweight, obesity, healthy lifestyleAbstract
Introduction and Objective: Obesity, as one of the diseases of civilization, has become a significant problem in our time. Although the first ways of treating it appeared many years ago, pharmacotherapy of obesity has been developing significantly in recent years.
The purpose of this article is to introduce the obesity drugs that have been registered for the treatment of obesity in Poland and to describe a new substance called tirzepatide, which, although it does not have such registration yet, is one of the most promising medications of the near future.
State of Knowledge: Obesity is an urgent and growing problem. In Poland, about 25% of adults are obese, and this number is increasing over the years.
In Europe, four drugs belonging to three different groups are registered for the treatment of obesity: orlistat, a combined drug that includes naltrexone hydrochloride and bupropion hydrochloride, liraglutide, and semaglutide. Although the last drug achieves the best results in studies and is the substance most favored by doctors and patients, there is still much research on new substances and formulations, which would bring even better results and health benefits. One of these substances is tirzepatide, a drug registered in 2022 for the treatment of type 2 diabetes.
Summary: Nowadays in Poland, there are four drugs registered for obesity. Two of them are representatives of the group of GLP-1 analogues.
Pharmacological treatment of obesity has good results and is a relatively safe process that should be implemented in conjunction with lifestyle changes. The fifth substance described in this article is tirzepatide, a drug that, although not registered for the treatment of obesity yet, is for now one of the most promising substances among the new drugs.
References
Rulkiewicz A, Pilchowska I, Lisik W, Pruszczyk P, Ciurzyński M, Domienik-Karłowicz J. Prevalence of Obesity and Severe Obesity among Professionally Active Adult Population in Poland and Its Strong Relationship with Cardiovascular Co-Morbidities-POL-O-CARIA 2016-2020 Study. J Clin Med 2022;11. https://doi.org/10.3390/jcm11133720.
Centrala NFZ - Aktualności / Aktualności / Narodowy Fundusz Zdrowia (NFZ) – finansujemy zdrowie Polaków n.d. https://www.nfz.gov.pl/aktualnosci/aktualnosci-centrali/prezentacja-raportu-cukier-otylosc-konsekwencje,7296.html (accessed January 9, 2024).
Panuganti KK, Nguyen M, Kshirsagar RK. Obesity. StatPearls, Treasure Island (FL): StatPearls Publishing; 2023.
World Obesity Day 2022 – Accelerating action to stop obesity n.d. https://www.who.int/news/item/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity (accessed January 8, 2024).
Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract 2017;29:S3–14. https://doi.org/10.1002/2327-6924.12510.
Dai H, Alsalhe TA, Chalghaf N, Riccò M, Bragazzi NL, Wu J. The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: An analysis of the Global Burden of Disease Study. PLoS Med 2020;17:e1003198. https://doi.org/10.1371/journal.pmed.1003198.
Bąk‑Sosnowska M., Białkowska M., Bogdański P., Chomiuk T., Gałązka‑Sobotka M., Holecki M., Jarosińska A., Jezierska M.,Kamiński P., Kłoda K., Kręgielska‑Narożna M., Lech M., Mamcarz A., Mastalerz‑Migas A., Matyjaszek‑Matuszek B., Ostrowska L.,Płaczkiewicz‑Jankowska E., Stachowska E., Stelmach‑Mardas M., Szeliga J., Szulińska M., Walczak M., Wyleżoł M.: Zalecenia kliniczne dotyczące postępowania u chorych na otyłość 2022 – stanowisko Polskiego Towarzystwa Leczenia Otyłości. Med. Prakt. wyd. specj.; maj 2022: 1–87 n.d.
Kwon Y-J, Kwon GE, Lee HS, Choi MH, Lee J-W. The effect of orlistat on sterol metabolism in obese patients. Front Endocrinol (Lausanne) 2022;13:824269. https://doi.org/10.3389/fendo.2022.824269.
Bansal AB, Al Khalili Y. Orlistat. StatPearls, Treasure Island (FL): StatPearls Publishing; 2023.
Jain SS, Ramanand SJ, Ramanand JB, Akat PB, Patwardhan MH, Joshi SR. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab 2011;15:99–104. https://doi.org/10.4103/2230-8210.81938.
Charakterystyka Produktu Leczniczego Orlistat Stada 60mg chpl.com.pl/data_files/2012-07-26_SPC_OrlistatSTADA_60mg__VarIA001_2012-06-11.pdf (accessed January 5, 2024) n.d.
Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis 2008;3:45–53. https://doi.org/10.2147/copd.s1121.
Charakterystyka Produktu Leczniczego Naltrexone Hydrochloride Accord, 50 mg, tabletki powlekane http://chpl.com.pl/data_files/2010-11-17_28.10.2010_accord_spc_final.pdf (accessed January 5, 2024)rd, 50 mg, tabletki powlekane n.d.
Charakterystyka Produktu Leczniczego Mysimba 8 mg + 90 mg tabletki o przedłużonym uwalnianiu https://urpl.gov.pl/sites/default/files/ChPL%20Mysimba%202016.pdf (accessed January 6, 2024) n.d.
Olszanecka-Glinianowicz M, Filipiak KJ, Narkiewicz K, Szelachowska M, Windak A, Czupryniak L, et al. Stanowisko Zespołu Ekspertów dotyczące zastosowania produktu leczniczego Mysimba® (chlorowodorek bupropionu i chlorowodorek naltreksonu) we wspomaganiu leczenia otyłości i nadwagi (BMI ≥ 27 kg/m2) z chorobami towarzyszącymi. Choroby Serca i Naczyń 2016.
Kulak-Bejda A, Bejda G, Waszkiewicz N. Safety and efficacy of naltrexone for weight loss in adult patients - a systematic review. Arch Med Sci 2021;17:940–53. https://doi.org/10.5114/aoms.2020.96908.
Latif W, Lambrinos KJ, Rodriguez R. Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs). StatPearls, Treasure Island (FL): StatPearls Publishing; 2023.
Anglart G, Dominiak K, Dettlaff K. Pharmacological treatment of obesity. Farm Pol 2023;78:654–66. https://doi.org/10.32383/farmpol/161473.
Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022;327:138–50. https://doi.org/10.1001/jama.2021.23619.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA 2023;330:1795–7. https://doi.org/10.1001/jama.2023.19574.
Charakterystyka Produktu Leczniczego Wegovy https://ec.europa.eu/health/documents/community-register/2023/20230331158642/anx_158642_pl.pdf, (accessed January 3, 2024) n.d.
Anglart G, Janik L, Dettlaff K. Tirzepatide – a new analogue of incretin hormones. Farm Pol 2023;79:289–96. https://doi.org/10.32383/farmpol/174068.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205–16. https://doi.org/10.1056/NEJMoa2206038.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503–15. https://doi.org/10.1056/NEJMoa2107519.
Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine 2023;58:101882. https://doi.org/10.1016/j.eclinm.2023.101882.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Barbara Woch, Dawid Bereza, Katarzyna Sokołowska, Maria Kulak, Igor Moreau, Paulina Polańska, Miriam Lang
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 472
Number of citations: 0
